ZURICH Wed Aug 6, 2014 7:30am EDT
The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel January 30, 2014.Credit: Reuters/Ruben Sprich
ZURICH (Reuters) - Roche said on Wednesday that European regulators approved its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy.
Avastin, which is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, was the Basel-based drugmaker's biggest seller last year with sales of 6.25 billion Swiss francs ($6.9 billion).
The move endorses a favorable recommendation last month from the European Medicine Agency's Committee for Medicinal Products for Human Use(CHMP), which are normally followed by the European Commission.
($1 = 0.9096 Swiss franc)
(Reporting By Katharina Bart; Editing by Maria Sheahan)
This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.